MA30023B1 - Nouvelle composition - Google Patents
Nouvelle compositionInfo
- Publication number
- MA30023B1 MA30023B1 MA30995A MA30995A MA30023B1 MA 30023 B1 MA30023 B1 MA 30023B1 MA 30995 A MA30995 A MA 30995A MA 30995 A MA30995 A MA 30995A MA 30023 B1 MA30023 B1 MA 30023B1
- Authority
- MA
- Morocco
- Prior art keywords
- lipopolysaccharide
- present
- saponin
- human dose
- adjuvant
- Prior art date
Links
- 239000002671 adjuvant Substances 0.000 abstract 3
- 239000002158 endotoxin Substances 0.000 abstract 3
- 229920006008 lipopolysaccharide Polymers 0.000 abstract 3
- 239000001397 quillaja saponaria molina bark Substances 0.000 abstract 3
- 229930182490 saponin Natural products 0.000 abstract 3
- 150000007949 saponins Chemical class 0.000 abstract 3
- 239000002502 liposome Substances 0.000 abstract 2
- 241001092142 Molina Species 0.000 abstract 1
- 241001454523 Quillaja saponaria Species 0.000 abstract 1
- 235000009001 Quillaja saponaria Nutrition 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 230000000890 antigenic effect Effects 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 230000002163 immunogen Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/002—Protozoa antigens
- A61K39/015—Hemosporidia antigens, e.g. Plasmodium antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
- A61K39/092—Streptococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/104—Pseudomonadales, e.g. Pseudomonas
- A61K39/1045—Moraxella
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5258—Virus-like particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6068—Other bacterial proteins, e.g. OMP
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10111—Atadenovirus, e.g. ovine adenovirus D
- C12N2710/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
- C12N2710/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
- C12N2710/16171—Demonstrated in vivo effect
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
- C12N2710/16734—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
- C12N2710/16771—Demonstrated in vivo effect
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20071—Demonstrated in vivo effect
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16171—Demonstrated in vivo effect
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16211—Influenzavirus B, i.e. influenza B virus
- C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16211—Influenzavirus B, i.e. influenza B virus
- C12N2760/16271—Demonstrated in vivo effect
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/20011—Rhabdoviridae
- C12N2760/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
La présente invention concerne une dose humaine d'une composition immunogène comprenant un antigène ou une préparation antigénique, en association avec un adjuvant, lequel adjuvant comprend une fraction immunologiquement active de saponine dérivée de l'écorce de Quillaja saponaria Molina présentée sous la forme d'un liposome et un lipopolysaccharide, ladite fraction de saponine et ledit lipopolysaccharide étant tous deux présents dans ladite dose humaine à un niveau inférieur à 30 µg. La présente invention concerne en plus une composition d'adjuvant dans un volume convenant pour une dose humaine comprenant entre 1 et 30 µg d'un lipopolysaccharide et entre 1 et 30 µg d'une fraction immunologiquement active de saponine présentée sous la forme d'un liposome.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0525321.6A GB0525321D0 (en) | 2005-12-13 | 2005-12-13 | Novel compositions |
GB0609902A GB0609902D0 (en) | 2006-05-18 | 2006-05-18 | Novel composition |
GBGB0620336.8A GB0620336D0 (en) | 2006-10-12 | 2006-10-12 | Vaccine |
GB0620337A GB0620337D0 (en) | 2006-10-12 | 2006-10-12 | Vaccine |
Publications (1)
Publication Number | Publication Date |
---|---|
MA30023B1 true MA30023B1 (fr) | 2008-12-01 |
Family
ID=37876836
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA30995A MA30023B1 (fr) | 2005-12-13 | 2008-06-03 | Nouvelle composition |
Country Status (29)
Country | Link |
---|---|
US (3) | US20080279926A1 (fr) |
EP (6) | EP2364723B1 (fr) |
JP (2) | JP5461015B2 (fr) |
KR (1) | KR101363879B1 (fr) |
CN (3) | CN103405764A (fr) |
AR (1) | AR058543A1 (fr) |
AT (1) | ATE542543T1 (fr) |
AU (1) | AU2006325377B2 (fr) |
BR (1) | BRPI0619795B8 (fr) |
CA (1) | CA2633008C (fr) |
CR (2) | CR10101A (fr) |
CY (3) | CY1112589T1 (fr) |
DK (3) | DK1959992T3 (fr) |
EA (2) | EA014353B1 (fr) |
ES (6) | ES2378471T3 (fr) |
HK (2) | HK1157219A1 (fr) |
HR (3) | HRP20120136T1 (fr) |
IL (2) | IL191703A (fr) |
MA (1) | MA30023B1 (fr) |
MY (1) | MY145943A (fr) |
NO (1) | NO20082472L (fr) |
NZ (2) | NZ568825A (fr) |
PE (1) | PE20071098A1 (fr) |
PL (3) | PL1959992T3 (fr) |
PT (3) | PT1959992E (fr) |
SG (2) | SG10201405533TA (fr) |
SI (3) | SI2364724T1 (fr) |
TW (1) | TWI457133B (fr) |
WO (1) | WO2007068907A2 (fr) |
Families Citing this family (79)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2707499T3 (es) | 2005-12-22 | 2019-04-03 | Glaxosmithkline Biologicals Sa | Vacuna de conjugado de polisacárido neumocócico |
JP5566687B2 (ja) * | 2006-06-15 | 2014-08-06 | ノバルティス アーゲー | アジュバントを使用しない複数回投与ワクチン接種レジメン |
RS54349B1 (en) | 2007-06-26 | 2016-02-29 | Glaxosmithkline Biologicals S.A. | VACCINE CONTAINING STREPTOCOCCUS PNEUMONIAE Capsular POLYSACCHARIDE CONJUGATES |
EP2034022A1 (fr) | 2007-09-10 | 2009-03-11 | Universite Libre De Bruxelles | Récepteur de la lipocaline soluble liant le leukotriène B4 issu de Ixodes ricinus |
EP2045263A1 (fr) | 2007-10-02 | 2009-04-08 | Universite Libre De Bruxelles | Identification et caractérisation moléculaire de métalloprotéases salivaires exprimées dans les glandes salivaires de la tique |
CN101952321B (zh) * | 2007-12-24 | 2016-05-11 | 葛兰素史密斯克莱生物公司 | 重组rsv抗原 |
WO2010094663A1 (fr) * | 2009-02-17 | 2010-08-26 | Glaxosmithkline Biologicals S.A. | Vaccin à virus inactivé contre la dengue, contenant un adjuvant sans aluminium |
GB0910046D0 (en) * | 2009-06-10 | 2009-07-22 | Glaxosmithkline Biolog Sa | Novel compositions |
CN104288763B (zh) * | 2009-06-19 | 2018-03-06 | 艾金株式会社 | 宫颈癌疫苗 |
DK2445526T3 (en) | 2009-06-24 | 2016-06-27 | Glaxosmithkline Biologicals Sa | Recombinant RSV antigens. |
SG176807A1 (en) | 2009-06-24 | 2012-01-30 | Id Biomedical Corp Quebec | Vaccine |
EP3178490B1 (fr) | 2009-07-15 | 2022-04-20 | GlaxoSmithKline Biologicals S.A. | Compositions à base de protéine f du vrs et procédés de fabrication associés |
CN102802664B (zh) * | 2009-12-22 | 2017-04-05 | 赛诺菲巴斯德有限公司 | 免疫原性组合物 |
CN101791401B (zh) * | 2009-12-31 | 2012-04-18 | 中国水产科学研究院黄海水产研究所 | 鱼用浸泡疫苗多组合佐剂及其应用和使用方法 |
BR112012018669A2 (pt) | 2010-01-27 | 2017-09-05 | Glaxosmithkline Biologicals Sa | Proteína rv3616c modificada, uso de uma proteína rv3616c modificada, polinucleotídeo, uso de um polinucleotídeo, composição farmacêutica, composição imunogênica, proteína de fusão, e, polipeptídeo. |
JP2017071615A (ja) * | 2010-10-27 | 2017-04-13 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | 神経障害を治療するための免疫原性組成物及び方法 |
GB201101331D0 (en) * | 2011-01-26 | 2011-03-09 | Glaxosmithkline Biolog Sa | Compositions and uses |
UY34073A (es) * | 2011-05-17 | 2013-01-03 | Glaxosmithkline Biolog Sa | Vacuna mejorada de streptococcus pneumoniae y métodos de preparación. |
GB201116248D0 (en) * | 2011-09-20 | 2011-11-02 | Glaxosmithkline Biolog Sa | Liposome production using isopropanol |
AU2012321022B2 (en) * | 2011-10-06 | 2017-03-23 | Immunovaccine Technologies Inc. | Liposome compositions comprising an adjuvant that activates or increases the activity of TLR2 and uses thereof |
GB201213364D0 (en) | 2012-07-27 | 2012-09-12 | Glaxosmithkline Biolog Sa | Purification process |
RU2645071C2 (ru) * | 2012-08-16 | 2018-02-15 | Пфайзер Инк. | Способы гликоконъюгирования и композиции |
EP2928489B1 (fr) | 2012-12-05 | 2019-02-27 | GlaxoSmithKline Biologicals S.A. | Composition immunogène |
EP3030260A1 (fr) * | 2013-08-05 | 2016-06-15 | GlaxoSmithKline Biologicals S.A. | Compositions immunogènes en combinaison |
CN105530954A (zh) * | 2013-10-03 | 2016-04-27 | 日东电工株式会社 | 鼻粘膜疫苗组合物 |
RU2016109150A (ru) | 2013-10-03 | 2017-11-10 | Нитто Денко Корпорейшн | Мукозальная вакцинная композиция |
US9962439B2 (en) | 2013-10-03 | 2018-05-08 | Nitto Denko Corporation | Injectable vaccine composition |
CN105530958A (zh) | 2013-10-03 | 2016-04-27 | 日东电工株式会社 | 粘膜疫苗组合物 |
GB201318862D0 (en) * | 2013-10-25 | 2013-12-11 | Glaxosmithkline Biolog Sa | Calcium fluoride compositions |
CN107124869B (zh) * | 2014-03-25 | 2022-04-01 | 美国政府陆军部 | 包含含有单磷酰脂质a(mpla)的脂质体组合物和皂苷的无毒佐剂制剂 |
GB201405921D0 (en) | 2014-04-02 | 2014-05-14 | Glaxosmithkline Biolog Sa | Novel methods for inducing an immune response |
US9107906B1 (en) | 2014-10-28 | 2015-08-18 | Adma Biologics, Inc. | Compositions and methods for the treatment of immunodeficiency |
CN107106675A (zh) * | 2014-12-18 | 2017-08-29 | 葛兰素史密丝克莱恩生物有限公司 | 疫苗接种 |
JP2018509384A (ja) | 2015-01-06 | 2018-04-05 | イミューノヴァクシーン テクノロジーズ インコーポレイテッドImmunovaccine Technologies Inc. | リピドa模倣体、調製方法、及びその使用 |
EP3347042A4 (fr) * | 2015-09-10 | 2019-02-20 | Inventprise, LLC. | Conjugués de ppv multivalents |
GB201518684D0 (en) | 2015-10-21 | 2015-12-02 | Glaxosmithkline Biolog Sa | Vaccine |
EP4001290A1 (fr) | 2015-11-06 | 2022-05-25 | Adjuvance Technologies, Inc. | Analogues de saponine triterpénique |
GB201522068D0 (en) * | 2015-12-15 | 2016-01-27 | Glaxosmithkline Biolog Sa | Dried composition |
BE1024160A9 (fr) | 2015-12-22 | 2017-12-06 | Glaxosmithkline Biologicals Sa | Formulation immunogène |
CN105770887A (zh) * | 2016-03-04 | 2016-07-20 | 邓招红 | 一种用于hbv疫苗的佐剂及其制备方法 |
US10611800B2 (en) | 2016-03-11 | 2020-04-07 | Pfizer Inc. | Human cytomegalovirus gB polypeptide |
US10695424B2 (en) | 2016-12-07 | 2020-06-30 | Glaxosmithkline Biologicals S.A. | Method of making a liposome composition |
WO2018144438A1 (fr) | 2017-01-31 | 2018-08-09 | Merck Sharp & Dohme Corp. | Procédés de production de conjugués protéine-polysaccharide capsulaire à partir du sérotype 19f de streptococcus pneumoniae |
US10259865B2 (en) | 2017-03-15 | 2019-04-16 | Adma Biologics, Inc. | Anti-pneumococcal hyperimmune globulin for the treatment and prevention of pneumococcal infection |
US11583578B2 (en) | 2017-04-28 | 2023-02-21 | The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. | Plasmodium falciparum recombinanr xiexumapoeozoite protein compositions and method for vaccine delivery |
AU2018330165A1 (en) | 2017-09-08 | 2020-04-02 | Access To Advanced Health Institute | Liposomal formulations comprising saponin and methods of use |
AU2018350887A1 (en) | 2017-10-16 | 2020-03-05 | Adjuvance Technologies, Inc. | Triterpene saponin analogues |
EP3717001A1 (fr) * | 2017-12-01 | 2020-10-07 | GlaxoSmithKline Biologicals S.A. | Purification de saponine |
BR112020010635A2 (pt) | 2017-12-01 | 2020-11-10 | Glaxosmithkline Biologicals S.A. | extração de saponina |
WO2019175145A1 (fr) | 2018-03-12 | 2019-09-19 | Janssen Vaccines & Prevention B.V. | Vaccins contre des infections des voies urinaires |
TWI820099B (zh) * | 2018-03-28 | 2023-11-01 | 台灣浩鼎生技股份有限公司 | 新穎皂素佐劑及其評估方法 |
US11547672B2 (en) | 2018-09-14 | 2023-01-10 | Massachusetts Institute Of Technology | Nanoparticle vaccine adjuvant and methods of use thereof |
US11629172B2 (en) | 2018-12-21 | 2023-04-18 | Pfizer Inc. | Human cytomegalovirus gB polypeptide |
WO2020154595A1 (fr) | 2019-01-24 | 2020-07-30 | Massachusetts Institute Of Technology | Plateforme de nanostructure d'acide nucléique pour présentation d'antigène et formulations de vaccin formées grâce à son utilisation |
US11446370B2 (en) | 2019-03-18 | 2022-09-20 | Janssen Pharmaceuticals, Inc. | Bioconjugates of E. coli o-antigen polysaccharides, methods of production thereof, and methods of use thereof |
MX2021011418A (es) | 2019-03-18 | 2021-10-13 | Janssen Pharmaceuticals Inc | Metodos de produccion de bioconjugados de polisacaridos de e. coli o- antigeno, sus composiciones y metodos de utilizacion. |
BR112022000710A2 (pt) | 2019-07-21 | 2022-03-22 | Glaxosmithkline Biologicals Sa | Vacina viral terapêutica |
EP3777884A1 (fr) | 2019-08-15 | 2021-02-17 | GlaxoSmithKline Biologicals S.A. | Composition immunogène |
KR20220107166A (ko) | 2019-10-02 | 2022-08-02 | 얀센 백신스 앤드 프리벤션 비.브이. | 스타필로코커스 펩티드 및 사용 방법 |
US20230045642A1 (en) | 2019-12-19 | 2023-02-09 | Glaxosmithkline Biologicals Sa | S. aureus antigens and compositions thereof |
BR112022013720A2 (pt) | 2020-01-16 | 2022-10-11 | Janssen Pharmaceuticals Inc | Mutante fimh, composições com o mesmo e seu uso |
AU2021219652A1 (en) | 2020-02-14 | 2022-08-18 | Merck Sharp & Dohme Llc | HPV vaccine |
WO2021195024A1 (fr) * | 2020-03-23 | 2021-09-30 | Adjuvance Technologies, Inc. | Composés adjuvants, formes salines et formulations |
EP4146378A1 (fr) * | 2020-05-05 | 2023-03-15 | GlaxoSmithKline Biologicals S.A. | Dispositif de mélange microfluidique et procédés d'utilisation |
US20230234992A1 (en) | 2020-06-05 | 2023-07-27 | Glaxosmithkline Biologicals Sa | Modified betacoronavirus spike proteins |
US11857622B2 (en) | 2020-06-21 | 2024-01-02 | Pfizer Inc. | Human cytomegalovirus GB polypeptide |
WO2022056195A1 (fr) * | 2020-09-10 | 2022-03-17 | The Rochester General Hospital | Vaccin contre haemophilus inenzae et méthodes d'utilisation |
KR20230043157A (ko) | 2020-09-17 | 2023-03-30 | 얀센 파마슈티칼즈, 인코포레이티드 | 다가 백신 조성물 및 이의 용도 |
CN116847830A (zh) | 2020-10-28 | 2023-10-03 | 赛诺菲巴斯德有限公司 | 含tlr4激动剂的脂质体、其制备和用途 |
GB2600468A (en) | 2020-10-30 | 2022-05-04 | Excivion Ltd | Adjuvant composition |
KR20230125842A (ko) | 2021-01-12 | 2023-08-29 | 얀센 파마슈티칼즈, 인코포레이티드 | FimH 돌연변이체, 이를 포함하는 조성물 및 이의 용도 |
EP4032547A1 (fr) | 2021-01-20 | 2022-07-27 | GlaxoSmithKline Biologicals S.A. | Fragments dérivés du hsv 1 fce pour le traitement du hsv |
BR112023019874A2 (pt) | 2021-04-01 | 2023-11-07 | Janssen Pharmaceuticals Inc | Produção de bioconjugados de e. coli o18 |
WO2023020994A1 (fr) * | 2021-08-16 | 2023-02-23 | Glaxosmithkline Biologicals Sa | Nouveaux procédés |
US20230118665A1 (en) * | 2021-08-19 | 2023-04-20 | Merck Sharp & Dohme Llc | Novel thermostable lipid nanoparticle and methods of use thereof |
US20230190920A1 (en) | 2021-12-19 | 2023-06-22 | Massachusetts Institute Of Technology | Compositions and methods for long-lasting germinal center responses to a priming immunization |
WO2023154960A1 (fr) | 2022-02-14 | 2023-08-17 | University Of Georgia Research Foundation, Inc. | Compositions de vaccins pan-pneumovirus et leurs méthodes d'utilisation |
WO2023175454A1 (fr) | 2022-03-14 | 2023-09-21 | Pfizer Inc. | Procédés de production d'adjuvant |
CN116162173A (zh) * | 2022-10-28 | 2023-05-26 | 安徽农业大学 | 一种GnRH6-CRM197重组蛋白去势疫苗及制备方法 |
Family Cites Families (191)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US666843A (en) * | 1900-07-02 | 1901-01-29 | Eastman Kodak Co | Spirit-level. |
US3238190A (en) | 1963-10-23 | 1966-03-01 | Madaus & Co K G Fa Dr | Aescin recovery |
DE2921961C2 (de) | 1979-05-30 | 1986-02-06 | Santrade Ltd., Luzern/Lucerne | Bohreinheit |
US4372945A (en) | 1979-11-13 | 1983-02-08 | Likhite Vilas V | Antigen compounds |
US4270537A (en) | 1979-11-19 | 1981-06-02 | Romaine Richard A | Automatic hypodermic syringe |
DD155875A1 (de) | 1980-12-31 | 1982-07-14 | Willy Nordheim | Verfahren zur herstellung eines ballaststoffarmen inaktivierten influenzaimpfstoffes |
IL61904A (en) | 1981-01-13 | 1985-07-31 | Yeda Res & Dev | Synthetic vaccine against influenza virus infections comprising a synthetic peptide and process for producing same |
US4866034A (en) | 1982-05-26 | 1989-09-12 | Ribi Immunochem Research Inc. | Refined detoxified endotoxin |
US4436727A (en) | 1982-05-26 | 1984-03-13 | Ribi Immunochem Research, Inc. | Refined detoxified endotoxin product |
DD211444A3 (de) | 1982-08-19 | 1984-07-11 | Saechsisches Serumwerk | Verfahren zur herstellung von influenza-impfstoffen |
US4596556A (en) | 1985-03-25 | 1986-06-24 | Bioject, Inc. | Hypodermic injection apparatus |
FI861417A0 (fi) | 1985-04-15 | 1986-04-01 | Endotronics Inc | Hepatitis b ytantigen framstaelld med rekombinant-dna-teknik, vaccin, diagnostiskt medel och cellinjer samt foerfaranden foer framstaellning daerav. |
DD300833A7 (de) | 1985-10-28 | 1992-08-13 | Saechsische Landesgewerbefoerd | Verfahren zur herstellung von inaktivierten influenza-vollvirusimpfstoffen |
US4877611A (en) | 1986-04-15 | 1989-10-31 | Ribi Immunochem Research Inc. | Vaccine containing tumor antigens and adjuvants |
US5173294A (en) | 1986-11-18 | 1992-12-22 | Research Foundation Of State University Of New York | Dna probe for the identification of haemophilus influenzae |
US4886499A (en) | 1986-12-18 | 1989-12-12 | Hoffmann-La Roche Inc. | Portable injection appliance |
US6222020B1 (en) | 1987-01-07 | 2001-04-24 | Imperial Cancer Research Technology Limited | Antigens derived from the core protein of the human mammary epithelial mucin |
JPH02501828A (ja) | 1987-01-07 | 1990-06-21 | インペリアル・キヤンサー・リサーチ・テクノロジー・リミテツド | プローブ |
GB8704027D0 (en) | 1987-02-20 | 1987-03-25 | Owen Mumford Ltd | Syringe needle combination |
US5057540A (en) | 1987-05-29 | 1991-10-15 | Cambridge Biotech Corporation | Saponin adjuvant |
JP2851288B2 (ja) | 1987-06-05 | 1999-01-27 | アメリカ合衆国 | 癌診断および管理における自己分泌運動性因子 |
US4940460A (en) | 1987-06-19 | 1990-07-10 | Bioject, Inc. | Patient-fillable and non-invasive hypodermic injection device assembly |
US4790824A (en) | 1987-06-19 | 1988-12-13 | Bioject, Inc. | Non-invasive hypodermic injection device |
US4941880A (en) | 1987-06-19 | 1990-07-17 | Bioject, Inc. | Pre-filled ampule and non-invasive hypodermic injection device assembly |
EP0304578B1 (fr) | 1987-06-22 | 2001-10-24 | Medeva Holdings Bv | Peptide contenant l'antigène de surface de l'hépatite B |
DE3734306A1 (de) | 1987-10-10 | 1989-04-27 | Pfeiffer Erich Gmbh & Co Kg | Austragvorrichtung fuer fliessfaehige medien |
US4963484A (en) | 1988-01-29 | 1990-10-16 | Dana-Farber Cancer Institute, Inc. | Genetically engineered polypeptides with determinants of the human DF3 breast carcinoma-associated antigen |
US5339163A (en) | 1988-03-16 | 1994-08-16 | Canon Kabushiki Kaisha | Automatic exposure control device using plural image plane detection areas |
US4912094B1 (en) | 1988-06-29 | 1994-02-15 | Ribi Immunochem Research Inc. | Modified lipopolysaccharides and process of preparation |
GB8819209D0 (en) | 1988-08-12 | 1988-09-14 | Research Corp Ltd | Polypeptide & dna encoding same |
FR2638359A1 (fr) | 1988-11-03 | 1990-05-04 | Tino Dalto | Guide de seringue avec reglage de la profondeur de penetration de l'aiguille dans la peau |
ES2160570T3 (es) | 1988-12-16 | 2001-11-16 | Nederlanden Staat | Mutantes de neumolisina y vacunas de neumococos fabricadas a partir de los mismos. |
GB8913737D0 (en) | 1989-06-15 | 1989-08-02 | Univ Birmingham | A novel anti-allergy treatment |
ES2109921T3 (es) | 1989-07-25 | 1998-02-01 | Smithkline Beecham Biolog | Nuevos antigenos y procedimientos para su preparacion. |
US5064413A (en) | 1989-11-09 | 1991-11-12 | Bioject, Inc. | Needleless hypodermic injection device |
US5312335A (en) | 1989-11-09 | 1994-05-17 | Bioject Inc. | Needleless hypodermic injection device |
DE4005528C2 (de) | 1990-02-22 | 1998-01-15 | Pfeiffer Erich Gmbh & Co Kg | Austragvorrichtung für Medien |
US5256643A (en) | 1990-05-29 | 1993-10-26 | The Government Of The United States | Human cripto protein |
SE466259B (sv) | 1990-05-31 | 1992-01-20 | Arne Forsgren | Protein d - ett igd-bindande protein fraan haemophilus influenzae, samt anvaendning av detta foer analys, vacciner och uppreningsaendamaal |
US5190521A (en) | 1990-08-22 | 1993-03-02 | Tecnol Medical Products, Inc. | Apparatus and method for raising a skin wheal and anesthetizing skin |
US5527288A (en) | 1990-12-13 | 1996-06-18 | Elan Medical Technologies Limited | Intradermal drug delivery device and method for intradermal delivery of drugs |
CA2059692C (fr) | 1991-01-28 | 2004-11-16 | Peter J. Kniskern | Vaccin conjugue de polysaccharide contre les pneumocoques |
CA2059693C (fr) | 1991-01-28 | 2003-08-19 | Peter J. Kniskern | Antigenes polysaccharides de streptococcus pneumoniae |
JP3215109B2 (ja) | 1991-02-15 | 2001-10-02 | ユーエイビー リサーチ ファウンデーション | 肺炎球菌タンパクの構造遺伝子 |
US6592876B1 (en) | 1993-04-20 | 2003-07-15 | Uab Research Foundation | Pneumococcal genes, portions thereof, expression products therefrom, and uses of such genes, portions and products |
US5476929A (en) | 1991-02-15 | 1995-12-19 | Uab Research Foundation | Structural gene of pneumococcal protein |
GB9113809D0 (en) | 1991-06-26 | 1991-08-14 | Cancer Res Campaign Tech | Papillomavirus l2 protein |
DE122007000018I1 (de) | 1991-07-19 | 2007-05-24 | Univ Queensland | Polynukleotidabschnitt des HPV16-Genoms |
US5552146A (en) | 1991-08-15 | 1996-09-03 | Board Of Regents, The University Of Texas System | Methods and compositions relating to useful antigens of Moraxella catarrhalis |
GB9118204D0 (en) | 1991-08-23 | 1991-10-09 | Weston Terence E | Needle-less injector |
SE9102652D0 (sv) | 1991-09-13 | 1991-09-13 | Kabi Pharmacia Ab | Injection needle arrangement |
WO1993010152A1 (fr) | 1991-11-16 | 1993-05-27 | Smithkline Beecham Biologicals S.A. | Proteine hybride entre la proteine cs de plasmodium et l'antigene de surface du virus de l'hepatite b |
US5328483A (en) | 1992-02-27 | 1994-07-12 | Jacoby Richard M | Intradermal injection device with medication and needle guard |
JPH06510799A (ja) | 1992-06-25 | 1994-12-01 | シティ・オブ・ホープ | サイトメガロウイルスのポリペプチドによる細胞溶解性t−リンパ球の誘導 |
SG49909A1 (en) * | 1992-06-25 | 1998-06-15 | Smithkline Beecham Biolog | Vaccine composition containing adjuvants |
WO1994000152A1 (fr) | 1992-06-25 | 1994-01-06 | Georgetown University | Vaccin contre le papillomavirus |
US5786148A (en) | 1996-11-05 | 1998-07-28 | Incyte Pharmaceuticals, Inc. | Polynucleotides encoding a novel prostate-specific kallikrein |
US5383851A (en) | 1992-07-24 | 1995-01-24 | Bioject Inc. | Needleless hypodermic injection device |
US5437951A (en) | 1992-09-03 | 1995-08-01 | The United States Of America As Represented By The Department Of Health And Human Services | Self-assembling recombinant papillomavirus capsid proteins |
US5569189A (en) | 1992-09-28 | 1996-10-29 | Equidyne Systems, Inc. | hypodermic jet injector |
US5334144A (en) | 1992-10-30 | 1994-08-02 | Becton, Dickinson And Company | Single use disposable needleless injector |
GB9224584D0 (en) | 1992-11-23 | 1993-01-13 | Connaught Lab | Use of outer membrane protein d15 and its peptides as vaccine against haempohilus influenzae diseases |
PT1618888E (pt) | 1993-03-09 | 2011-04-08 | Univ Rochester | Produção de proteína da cápside de vírus de papiloma humano e partículas semelhantes a vírus |
US5801005A (en) | 1993-03-17 | 1998-09-01 | University Of Washington | Immune reactivity to HER-2/neu protein for diagnosis of malignancies in which the HER-2/neu oncogene is associated |
CN1087176C (zh) | 1993-03-23 | 2002-07-10 | 史密斯克莱·比奇曼生物公司 | 含有3-o脱酰基单磷酰脂a的疫苗制剂 |
ES2185658T3 (es) | 1993-05-18 | 2003-05-01 | Univ Ohio State Res Found | Vacuna para la otitis media. |
US5744144A (en) | 1993-07-30 | 1998-04-28 | University Of Pittsburgh University Patent Committee Policy And Procedures | Synthetic multiple tandem repeat mucin and mucin-like peptides, and uses thereof |
JP3828145B2 (ja) | 1993-09-22 | 2006-10-04 | ヘンリー エム.ジャクソン ファウンデイション フォー ザ アドバンスメント オブ ミリタリー メディスン | 免疫原性構成物の製造のための新規シアン化試薬を使った可溶性炭水化物の活性化方法 |
BE1007535A3 (nl) | 1993-09-24 | 1995-07-25 | Innovative Sputtering Tech | Gelaagde metaalstructuur. |
GB9326253D0 (en) * | 1993-12-23 | 1994-02-23 | Smithkline Beecham Biolog | Vaccines |
US5688506A (en) | 1994-01-27 | 1997-11-18 | Aphton Corp. | Immunogens against gonadotropin releasing hormone |
WO1995024176A1 (fr) | 1994-03-07 | 1995-09-14 | Bioject, Inc. | Dispositif de remplissage d'ampoule |
US5466220A (en) | 1994-03-08 | 1995-11-14 | Bioject, Inc. | Drug vial mixing and transfer device |
GB9409962D0 (en) | 1994-05-18 | 1994-07-06 | Smithkline Beecham Biolog | Novel compounds |
US5565204A (en) | 1994-08-24 | 1996-10-15 | American Cyanamid Company | Pneumococcal polysaccharide-recombinant pneumolysin conjugate vaccines for immunization against pneumococcal infections |
AU4270196A (en) | 1994-10-07 | 1996-05-02 | Lutz Gissmann | Papilloma virus-like particles, fusion proteins and process for producing the same |
US5599302A (en) | 1995-01-09 | 1997-02-04 | Medi-Ject Corporation | Medical injection system and method, gas spring thereof and launching device using gas spring |
EP0812358A1 (fr) | 1995-02-24 | 1997-12-17 | Cantab Pharmaceuticals Research Limited | Polypeptides utiles comme agents immunotherapeutiques et procedes de preparation de polypeptides |
IL117459A (en) | 1995-03-22 | 2005-11-20 | Merck & Co Inc | Dna encoding human papillomavirus type 18 |
US20030219453A1 (en) * | 1998-03-19 | 2003-11-27 | Smithkline Beecham Biologicals, Sa | Vaccines |
US20010053365A1 (en) * | 1995-04-25 | 2001-12-20 | Smithkline Beecham Biologicals S.A. | Vaccines |
GB9620795D0 (en) * | 1996-10-05 | 1996-11-20 | Smithkline Beecham Plc | Vaccines |
UA56132C2 (uk) * | 1995-04-25 | 2003-05-15 | Смітклайн Бічем Байолоджікалс С.А. | Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини |
US6440425B1 (en) | 1995-05-01 | 2002-08-27 | Aventis Pasteur Limited | High molecular weight major outer membrane protein of moraxella |
US5688267A (en) * | 1995-05-01 | 1997-11-18 | Ep Technologies, Inc. | Systems and methods for sensing multiple temperature conditions during tissue ablation |
US5730723A (en) | 1995-10-10 | 1998-03-24 | Visionary Medical Products Corporation, Inc. | Gas pressured needle-less injection device and method |
US5668267A (en) | 1995-05-31 | 1997-09-16 | Washington University | Polynucleotides encoding mammaglobin, a mammary-specific breast cancer protein |
US5843464A (en) | 1995-06-02 | 1998-12-01 | The Ohio State University | Synthetic chimeric fimbrin peptides |
US5981215A (en) | 1995-06-06 | 1999-11-09 | Human Genome Sciences, Inc. | Human criptin growth factor |
EA199800046A1 (ru) | 1995-06-07 | 1998-06-25 | Байокем Вэксинс Инк. | Полипептид, последовательность днк, вакцинная композиция (варианты), антитело или его фрагмент, вакцина, применения указанных полипептида, последовательности днк и антитела или его фрагмента |
GB9513074D0 (en) | 1995-06-27 | 1995-08-30 | Cortecs Ltd | Novel anigen |
US6290970B1 (en) | 1995-10-11 | 2001-09-18 | Aventis Pasteur Limited | Transferrin receptor protein of Moraxella |
US5997881A (en) | 1995-11-22 | 1999-12-07 | University Of Maryland, Baltimore | Method of making non-pyrogenic lipopolysaccharide or A |
US5893397A (en) | 1996-01-12 | 1999-04-13 | Bioject Inc. | Medication vial/syringe liquid-transfer apparatus |
US6090576A (en) | 1996-03-08 | 2000-07-18 | Connaught Laboratories Limited | DNA encoding a transferrin receptor of Moraxella |
GB9607549D0 (en) | 1996-04-11 | 1996-06-12 | Weston Medical Ltd | Spring-powered dispensing device |
CA2253252A1 (fr) | 1996-05-01 | 1997-11-06 | The Rockefeller University | Proteines fixant la choline pour vaccins anti-pneumococciiques |
US7341727B1 (en) | 1996-05-03 | 2008-03-11 | Emergent Product Development Gaithersburg Inc. | M. catarrhalis outer membrane protein-106 polypeptide, methods of eliciting an immune response comprising same |
EP0956289A4 (fr) | 1996-08-16 | 2004-10-13 | Smithkline Beecham Corp | Nouveaux polynucleotides et polypeptides procaryotes et leurs utilisations |
US5955306A (en) | 1996-09-17 | 1999-09-21 | Millenium Pharmaceuticals, Inc. | Genes encoding proteins that interact with the tub protein |
US5882896A (en) | 1996-09-24 | 1999-03-16 | Smithkline Beecham Corporation | M protein |
US5882871A (en) | 1996-09-24 | 1999-03-16 | Smithkline Beecham Corporation | Saliva binding protein |
EP1770164B1 (fr) | 1996-10-31 | 2010-09-01 | Human Genome Sciences, Inc. | Antigènes et vaccins pour streptococcus pneumoniae |
WO1998021337A2 (fr) | 1996-11-12 | 1998-05-22 | Regents Of The University Of Minnesota | Proteine de liaison c3 de streptococcus pneumoniae |
US5840871A (en) | 1997-01-29 | 1998-11-24 | Incyte Pharmaceuticals, Inc. | Prostate-associated kallikrein |
WO1998033923A1 (fr) | 1997-01-30 | 1998-08-06 | Imperial College Of Science, Technology & Medicine | GENES MUTANTS msbB ou $i(htrB) |
JP3844366B2 (ja) | 1997-02-25 | 2006-11-08 | コリクサ コーポレイション | 前立腺ガンの免疫診断のための化合物およびそれらの使用方法 |
JP3036686B2 (ja) | 1997-02-27 | 2000-04-24 | 政夫 高橋 | 冠状動脈のバイパス手術に用いる血管吻合部の止血保持装置 |
DE19708537A1 (de) | 1997-03-03 | 1998-09-10 | Biotechnolog Forschung Gmbh | Neues Oberflächenprotein (SpsA-Protein) von Streptococcus pneumoniae etc. |
JP5019494B2 (ja) * | 1997-04-01 | 2012-09-05 | コリクサ コーポレーション | モノホスホリルリピドaの水性免疫アジュバント組成物 |
ZA982968B (en) | 1997-04-09 | 1998-10-27 | Corixa Corp | Compositions and methods for the treatment and diagnosis of breast cancer |
WO1998050567A1 (fr) | 1997-05-02 | 1998-11-12 | Abbott Laboratories | Reactifs et procedes pour detecter les maladies de la prostate |
US5993412A (en) | 1997-05-19 | 1999-11-30 | Bioject, Inc. | Injection apparatus |
WO1998055606A2 (fr) | 1997-06-03 | 1998-12-10 | Connaught Laboratories Limited | Genes du recepteur de la lactoferrine de moraxella |
GB9712347D0 (en) | 1997-06-14 | 1997-08-13 | Smithkline Beecham Biolog | Vaccine |
WO1999003884A2 (fr) | 1997-07-21 | 1999-01-28 | North American Vaccine, Inc. | Compositions de pneumolysine immunogene modifiee utiles en tant que vaccins |
US5928215A (en) * | 1997-08-14 | 1999-07-27 | Becton, Dickinson And Acompany | Syringe filling and delivery device |
GB9717953D0 (en) | 1997-08-22 | 1997-10-29 | Smithkline Beecham Biolog | Vaccine |
AU742409B2 (en) | 1997-09-05 | 2002-01-03 | Medimmune, Llc | In vitro method for disassembly/reassembly of papillomavirus virus-like particles (VLPs) |
EP1279401B1 (fr) * | 1997-09-05 | 2008-01-09 | GlaxoSmithKline Biologicals S.A. | Emulsions du type huile-dans-l'eau contenant des saponines |
BR9812525A (pt) | 1997-09-24 | 2000-07-25 | Univ Minnesota | Proteinase degradadora de complemento humano c3 de streptococcus pneumoniae |
AU2447999A (en) | 1997-09-26 | 1999-05-03 | Corixa Corporation | Murine model for human carcinoma |
WO1999033869A2 (fr) | 1997-12-24 | 1999-07-08 | Corixa Corporation | Composes destines a l'immunotherapie et au diagnostic du cancer du sein, et leur mode d'utilisation |
IT1298087B1 (it) | 1998-01-08 | 1999-12-20 | Fiderm S R L | Dispositivo per il controllo della profondita' di penetrazione di un ago, in particolare applicabile ad una siringa per iniezioni |
SI1659179T1 (sl) | 1998-02-05 | 2011-10-28 | Glaxosmithkline Biolog Sa | S tumorjem povezani antigenski derivati iz MAGE druĹľine in zaporedja nukleinskih kislin, ki jih kodirajo, uporabni za pripravo fuzijskih proteinov in sestavkov za cepljenje |
US20020039584A1 (en) | 1998-02-20 | 2002-04-04 | Medigene Ag | Papilloma virus capsomere vaccine formulations and methods of use |
HUP0102306A3 (en) | 1998-04-07 | 2008-04-28 | St Jude Childrens Res Hospital | A polypeptide comprising the amino acid of an n-terminal choline binding protein a truncate, vaccine derived therefrom and uses thereof |
CZ302870B6 (cs) | 1998-04-07 | 2011-12-28 | Corixa Corporation | Polynukleotid, polypeptid, farmaceutický prostredek, vakcínový prostredek a jejich použití k lécbe a prevenci infekce tuberkulózou |
WO1999051266A2 (fr) | 1998-04-07 | 1999-10-14 | Medimmune, Inc. | Derives de proteines pneumococciques de liaison de choline destines a des vaccins |
EP1073734B1 (fr) | 1998-04-15 | 2009-09-23 | Ludwig Institute for Cancer Research Ltd. | Acides nucleiques associes a des tumeurs et leur emploi |
JP2002516251A (ja) | 1998-04-23 | 2002-06-04 | ユーエイビー リサーチ ファンデーション | 肺炎球菌表面プロテインC(PspC)のエピトープ領域およびその菌株選択、ならびにそのための使用法 |
GB9809683D0 (en) | 1998-05-06 | 1998-07-01 | Smithkline Beecham Biolog | Novel compounds |
GB9810285D0 (en) | 1998-05-13 | 1998-07-15 | Smithkline Beecham Biolog | Novel compounds |
AU738896B2 (en) | 1998-06-03 | 2001-09-27 | Smithkline Beecham Biologicals (Sa) | BASB027 proteins and genes from Moraxella catarrhalis, antigens, antibodies, and uses |
GB9812163D0 (en) | 1998-06-05 | 1998-08-05 | Smithkline Beecham Biolog | Novel compounds |
GB9812440D0 (en) | 1998-06-09 | 1998-08-05 | Smithkline Beecham Biolog | Novel compounds |
GB9812613D0 (en) | 1998-06-11 | 1998-08-12 | Smithkline Beecham Biolog | Vaccine |
TW200728465A (en) | 1998-07-14 | 2007-08-01 | Corixa Corp | Compositions and methods for the therapy and diagnosis of prostate cancer |
GB9820002D0 (en) | 1998-09-14 | 1998-11-04 | Smithkline Beecham Biolog | Novel compounds |
KR20010089280A (ko) | 1998-09-24 | 2001-09-29 | 리전츠 오브 더 유니버스티 오브 미네소타 | 스트렙토코쿠스 뉴모니애로부터의 인간 보체 c3 분해폴리펩티드 |
GB2359228A (en) | 1998-11-17 | 2001-08-15 | Schlumberger Technology Corp | Transmitting information over a communication link |
WO2000029434A2 (fr) | 1998-11-19 | 2000-05-25 | St. Jude Children's Research Hospital | IDENTIFICATION ET CARACTERISATION DE NOUVELLES PROTEINES PNEUMOCOCCIQUES SE LIANT A LA CHOLINE, CbpG AND CbpD, ET UTILISATIONS DIAGNOSTIQUES ET THERAPEUTIQUES CORRESPONDANTES |
ATE422899T1 (de) | 1998-12-21 | 2009-03-15 | Medimmune Inc | Streptococcus pneumoniae proteine und immunogene fragmente für impstoffe |
CZ20012587A3 (cs) | 1999-01-29 | 2002-05-15 | Corixa Corporation | Izolovaný protein, nukleová kyselina, virový vektor, farmaceutický prostředek, izolovaná populace T buněk, způsob posílení imunitní odpovědi, způsob odstranění nádorových buněk, způsob stimulace a/nebo namnoľení T buněk a způsob přípravy fúzního proteinu |
GB9904559D0 (en) | 1999-02-26 | 1999-04-21 | Smithkline Beecham Biolog | Novel compounds |
WO2000052165A2 (fr) | 1999-03-04 | 2000-09-08 | Corixa Corporation | Compositions et methodes de therapie et de diagnostic du cancer du sein |
SI1162999T1 (sl) | 1999-03-19 | 2007-04-30 | Glaxosmithkline Biolog Sa | Vakcina proti Streptococcus pneumoniae |
US6245568B1 (en) | 1999-03-26 | 2001-06-12 | Merck & Co., Inc. | Human papilloma virus vaccine with disassembled and reassembled virus-like particles |
ES2228497T3 (es) | 1999-04-19 | 2005-04-16 | Glaxosmithkline Biologicals S.A. | Composicion adyuvante que comprende saponina y un oligonucleotido inmunoestimulante. |
ATE500843T1 (de) | 1999-06-10 | 2011-03-15 | Medimmune Llc | Streptococcus pneumoniae proteine und impfstoffe |
FR2796291B1 (fr) | 1999-07-16 | 2001-09-21 | Cross Site Technologies | Seringue sans aiguille munie d'un systeme de declenchement piezo-electrique |
FR2796290B1 (fr) | 1999-07-16 | 2001-09-14 | Cross Site Technologies | Seringue sans aiguille fonctionnant avec un generateur d'onde de choc a travers une paroi |
FR2796289B1 (fr) | 1999-07-16 | 2001-08-10 | Cross Site Technologies | Seringue sans aiguille avec injecteur a elements superposes |
GB9917977D0 (en) | 1999-07-30 | 1999-09-29 | Smithkline Beecham Biolog | Novel compounds |
GB9918038D0 (en) | 1999-07-30 | 1999-09-29 | Smithkline Beecham Biolog | Novel compounds |
GB9918302D0 (en) | 1999-08-03 | 1999-10-06 | Smithkline Beecham Biolog | Novel compounds |
GB9918208D0 (en) | 1999-08-03 | 1999-10-06 | Smithkline Beecham Biolog | Novel compounds |
US6139179A (en) | 1999-09-03 | 2000-10-31 | Davis-Standard Corporation | Extruder screw having multi-channeled barrier section |
GB9921146D0 (en) | 1999-09-07 | 1999-11-10 | Smithkline Beecham Biolog | Novel composition |
GB9921147D0 (en) | 1999-09-07 | 1999-11-10 | Smithkline Beecham Biolog | Novel composition |
US6494865B1 (en) | 1999-10-14 | 2002-12-17 | Becton Dickinson And Company | Intradermal delivery device including a needle assembly |
FR2800619B1 (fr) | 1999-11-05 | 2002-02-08 | Cross Site Technologies | Seringue sans aiguille avec un moyen de poussee temporairement retenu |
FR2802103B1 (fr) | 1999-12-08 | 2003-10-03 | Poudres & Explosifs Ste Nale | Seringue sans aiguille fonctionnant avec entrainement du principe actif par effet tube a choc |
FR2802102B1 (fr) * | 1999-12-08 | 2002-07-12 | Poudres & Explosifs Ste Nale | Seringue sans aiguille munie d'un tube d'ejection a section constante |
FR2802820B1 (fr) * | 1999-12-27 | 2002-10-18 | Poudres & Explosifs Ste Nale | Seringue sans aiguille fonctionnant par effet tube a choc, avec maintien prealable du principe actif sur le cote |
FR2804329B1 (fr) * | 2000-02-02 | 2002-12-13 | Poudres & Explosifs Ste Nale | Seringue sans aiguille munie d'un opercule contenant le principe actif |
FR2804869B1 (fr) * | 2000-02-11 | 2002-05-17 | Poudres & Explosifs Ste Nale | Seringue sans aiguille pour l'injection d'un liquide contenu dans une ampoule pre-remplie |
FR2805749B1 (fr) | 2000-03-01 | 2002-05-17 | Poudres & Explosifs Ste Nale | Seringue sans aiguille a deux niveaux de vitesse d'injection |
FR2807946B1 (fr) * | 2000-04-19 | 2002-06-07 | Poudres & Explosifs Ste Nale | Seringue sans aiguille fonctionnant avec un chargement pyrotechnique bicomposition |
FR2809626B1 (fr) | 2000-05-30 | 2003-03-07 | Poudres & Explosifs Ste Nale | Seringue sans aiguille avec membrane d'isolation d'un ejecteur multiconduit |
AU7038101A (en) | 2000-06-20 | 2002-01-02 | Shire Biochem Inc | Streptococcus antigens |
FR2810554B1 (fr) * | 2000-06-22 | 2003-05-16 | Poudres & Explosifs Ste Nale | Seringue sans aiguille munie d'un reservoir modulable |
FR2812202B1 (fr) | 2000-07-28 | 2002-09-13 | Poudres & Explosifs Ste Nale | Seringue sans aiguille fonctionnant par mise en compression du reservoir contenant le principe actif liquide |
GB0019375D0 (en) | 2000-08-07 | 2000-09-27 | Int Centre Genetic Eng & Bio | Method of polypeptide renaturation |
GB0022742D0 (en) | 2000-09-15 | 2000-11-01 | Smithkline Beecham Biolog | Vaccine |
GB0025577D0 (en) * | 2000-10-18 | 2000-12-06 | Smithkline Beecham Biolog | Vaccine |
FR2815544B1 (fr) * | 2000-10-23 | 2003-02-14 | Poudres & Explosifs Ste Nale | Seringue sans aiguille securisee a architecture compacte |
US20040096463A1 (en) | 2001-02-23 | 2004-05-20 | Nathalie Garcon | Novel vaccine |
US20030031684A1 (en) | 2001-03-30 | 2003-02-13 | Corixa Corporation | Methods for the production of 3-O-deactivated-4'-monophosphoryl lipid a (3D-MLA) |
MY134424A (en) | 2001-05-30 | 2007-12-31 | Saechsisches Serumwerk | Stable influenza virus preparations with low or no amount of thiomersal |
GB0123580D0 (en) * | 2001-10-01 | 2001-11-21 | Glaxosmithkline Biolog Sa | Vaccine |
CA2462203A1 (fr) * | 2001-10-12 | 2003-11-20 | University Of Iowa Research Foundation | Methodes et produits permettant d'ameliorer des reponses immunitaires a l'aide de compose d'imidazoquinoline |
EP1456231A2 (fr) | 2001-12-20 | 2004-09-15 | Shire Biochem Inc. | Antigenes de streptococcus |
US7026465B2 (en) | 2002-02-15 | 2006-04-11 | Corixa Corporation | Fusion proteins of Mycobacterium tuberculosis |
EP1551221A4 (fr) * | 2002-07-03 | 2007-08-01 | Coley Pharm Group Inc | Compositions d'acide nucleique destinees a stimuler les reponses immunitaires |
CA2565500A1 (fr) * | 2004-05-28 | 2005-12-15 | Glaxosmithkline Biologicals S.A. | Compositions de vaccin comprenant des virosomes et un adjuvant a base de saponine |
GB0504436D0 (en) * | 2005-03-03 | 2005-04-06 | Glaxosmithkline Biolog Sa | Vaccine |
EA014527B1 (ru) | 2005-03-31 | 2010-12-30 | Глаксосмитклайн Байолоджикалс С.А. | Вакцины против хламидиоза |
MX2007013472A (es) | 2005-04-26 | 2008-04-02 | Glaxosmithkline Biolog Sa | Vacuna. |
PL1877426T3 (pl) | 2005-04-29 | 2012-10-31 | Glaxosmithkline Biologicals Sa | Sposób profilaktyki lub leczenia zakażenia M. tuberculosis |
BRPI0610061A2 (pt) * | 2005-05-19 | 2016-11-29 | Glaxosmithkline Biolog Sa | composição de vacina, uso de subunidade b de toxina instável ao calor de e. coli ou um derivado da mesma, métodos para tratar ou previnir doença, para desenvolver uma resposta imune cd8 específica para antígeno, e, processo para produzir uma vacina |
-
2006
- 2006-12-11 TW TW095146300A patent/TWI457133B/zh not_active IP Right Cessation
- 2006-12-12 CN CN2013103564887A patent/CN103405764A/zh active Pending
- 2006-12-12 ES ES06831376T patent/ES2378471T3/es active Active
- 2006-12-12 EP EP11168826.3A patent/EP2364723B1/fr active Active
- 2006-12-12 KR KR1020087016980A patent/KR101363879B1/ko active IP Right Grant
- 2006-12-12 CA CA2633008A patent/CA2633008C/fr active Active
- 2006-12-12 AT AT06831376T patent/ATE542543T1/de active
- 2006-12-12 CN CN2012101089032A patent/CN102631670A/zh active Pending
- 2006-12-12 ES ES11168821.4T patent/ES2445170T3/es active Active
- 2006-12-12 EP EP06831376A patent/EP1959992B1/fr active Active
- 2006-12-12 EP EP11168827.1A patent/EP2364724B1/fr active Active
- 2006-12-12 ES ES11168820.6T patent/ES2479165T3/es active Active
- 2006-12-12 MY MYPI20082050A patent/MY145943A/en unknown
- 2006-12-12 DK DK06831376.6T patent/DK1959992T3/da active
- 2006-12-12 SI SI200631697T patent/SI2364724T1/sl unknown
- 2006-12-12 DK DK11168820.6T patent/DK2364720T3/da active
- 2006-12-12 US US12/096,838 patent/US20080279926A1/en not_active Abandoned
- 2006-12-12 JP JP2008545078A patent/JP5461015B2/ja active Active
- 2006-12-12 BR BRPI0619795A patent/BRPI0619795B8/pt active IP Right Grant
- 2006-12-12 AU AU2006325377A patent/AU2006325377B2/en active Active
- 2006-12-12 NZ NZ568825A patent/NZ568825A/en not_active IP Right Cessation
- 2006-12-12 ES ES11168822.2T patent/ES2444623T3/es active Active
- 2006-12-12 PT PT06831376T patent/PT1959992E/pt unknown
- 2006-12-12 EA EA200801307A patent/EA014353B1/ru not_active IP Right Cessation
- 2006-12-12 EP EP11168822.2A patent/EP2364722B1/fr active Active
- 2006-12-12 SG SG10201405533TA patent/SG10201405533TA/en unknown
- 2006-12-12 CN CN201410035418.6A patent/CN103861100A/zh active Pending
- 2006-12-12 DK DK11168827.1T patent/DK2364724T3/da active
- 2006-12-12 PT PT111688206T patent/PT2364720E/pt unknown
- 2006-12-12 SI SI200631793T patent/SI2364720T1/sl unknown
- 2006-12-12 EA EA201001189A patent/EA018860B1/ru not_active IP Right Cessation
- 2006-12-12 ES ES11168827.1T patent/ES2436645T3/es active Active
- 2006-12-12 PL PL06831376T patent/PL1959992T3/pl unknown
- 2006-12-12 ES ES11168826.3T patent/ES2451573T3/es active Active
- 2006-12-12 SG SG201101856-1A patent/SG170127A1/en unknown
- 2006-12-12 NZ NZ596870A patent/NZ596870A/xx not_active IP Right Cessation
- 2006-12-12 EP EP11168821.4A patent/EP2364721B1/fr active Active
- 2006-12-12 PT PT111688271T patent/PT2364724E/pt unknown
- 2006-12-12 WO PCT/GB2006/004634 patent/WO2007068907A2/fr active Application Filing
- 2006-12-12 PL PL11168820T patent/PL2364720T3/pl unknown
- 2006-12-12 PL PL11168827T patent/PL2364724T3/pl unknown
- 2006-12-12 SI SI200631300T patent/SI1959992T1/sl unknown
- 2006-12-12 EP EP11168820.6A patent/EP2364720B1/fr active Active
- 2006-12-13 AR ARP060105496A patent/AR058543A1/es not_active Application Discontinuation
- 2006-12-13 PE PE2006001600A patent/PE20071098A1/es not_active Application Discontinuation
-
2008
- 2008-05-26 IL IL191703A patent/IL191703A/en active IP Right Grant
- 2008-05-29 NO NO20082472A patent/NO20082472L/no not_active Application Discontinuation
- 2008-06-03 MA MA30995A patent/MA30023B1/fr unknown
- 2008-06-20 CR CR10101A patent/CR10101A/es not_active Application Discontinuation
- 2008-06-26 CR CR10118A patent/CR10118A/xx unknown
- 2008-09-16 HK HK11111652.3A patent/HK1157219A1/xx not_active IP Right Cessation
- 2008-09-16 HK HK08110254.2A patent/HK1118477A1/xx not_active IP Right Cessation
-
2011
- 2011-02-03 US US13/020,045 patent/US10039823B2/en active Active
-
2012
- 2012-02-10 HR HR20120136T patent/HRP20120136T1/hr unknown
- 2012-03-30 CY CY20121100324T patent/CY1112589T1/el unknown
- 2012-11-22 JP JP2012256348A patent/JP2013056927A/ja active Pending
-
2013
- 2013-11-06 HR HRP20131057TT patent/HRP20131057T1/hr unknown
- 2013-11-20 IL IL229521A patent/IL229521A0/en unknown
- 2013-11-22 CY CY20131101050T patent/CY1114864T1/el unknown
-
2014
- 2014-05-28 HR HRP20140484TT patent/HRP20140484T1/hr unknown
- 2014-06-25 CY CY20141100461T patent/CY1115308T1/el unknown
-
2016
- 2016-11-17 US US15/354,233 patent/US10143745B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA30023B1 (fr) | Nouvelle composition | |
MA31381B1 (fr) | Vaccin contre la grippe a emulsion huile dans l'eau | |
MA30866B1 (fr) | Vaccin | |
MA27729A1 (fr) | Compositions pharmaceutiques solides contenant un agoniste des recepteurs de la s1p et un alcool de sucre | |
MA30298B1 (fr) | Composition | |
MA29321B1 (fr) | Vaccin a base de rotavirus vivant attenue pour administration orale | |
TR200002930T2 (tr) | Kolaylaştırıcı kompozisyonlar | |
BR0310062A (pt) | Vacinas mucosas com adjuvante de quitosana e/ou antìgenos meningocócicos | |
AR108718A2 (es) | Composición | |
MA29714B1 (fr) | Vaccin | |
HK1113971A1 (en) | Oral formulations for delivery of catecholic butanes including ndga compounds | |
MA30624B1 (fr) | Vaccin anti-grippal | |
BRPI0518091A2 (pt) | mycobacterium, mÉtodo para permitir com que uma mycobacterium escape a partir de endossomos e preparaÇço para uma vacina | |
DK1741442T3 (da) | Neisseria meningitidis-kombinationavacciner | |
AU2457100A (en) | Enhancement of bactericidal activity of neisseria antigens with oligonucleotidescontaining cg motifs | |
MX2010004271A (es) | Formulaciones de vacuna meningococica. | |
MA29273B1 (fr) | Combinaison synergique de xolair/omalizumab/e25 et d'un agent immunosuppresseur | |
ES2195169T3 (es) | Vacunas contra calmidias y composiciones inmunogenicas que contienen un antigeno de membrana externa y metodos para su preparacion. | |
MA30691B1 (fr) | Compositions pharmaceutiques contenant un anticorps monoclonal anti-idiotypique anti-ca-125 et de l'aluminium. | |
BRPI0414073A (pt) | método para induzir uma resposta imune contra infecção por rotavìrus a partir de um sorotipo de rotavìrus, e, uso de uma cepa de rotavìrus atenuado de um sorotipo | |
FR3092754B1 (fr) | Composition adjuvante pour vaccin | |
EP2433648A3 (fr) | Vaccin comprenant une émulsion adjuvante huile en l'eau | |
ATE260118T1 (de) | Zusammensetzungen von adenosin a1 agonisten mit 5ht1 agonisten | |
FR2992864A1 (fr) | Emulsion anti-tumorale a base de lipiodol pour le traitement du cancer | |
MX2009010963A (es) | Vacuna de influenza de emulsion de aceite en agua. |